PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
View original at finance.yahoo.com“PDS Biotechnology reported a net loss of $7.3 million for Q1 2026, an improvement from $8.5 million in Q1 2025... Mr. Bozgaard will review the financial results for the quarter ended March 31, 2026.”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
PDS Biotechnology reported a net loss of $7.3 million for Q1 2026
60% confidencePositive results from PDS01 ADC trials in prostate and colorectal cancer support its potential across multiple solid tumor types
60% confidenceNew patents for PDS0101 in the US and Japan extend market protection into the 2040s
60% confidenceQ1 2026 net loss of $7.3 million represents an improvement from the $8.5 million net loss in Q1 2025
60% confidenceDuring this call, forward-looking statements are being made which are subject to various risks and uncertainties that could cause actual results to differ materially
60% confidenceManagement is focusing on advancing PDS0101 as a treatment for HPV 16 positive cancers, with late-stage trials in collaboration with key institutions
60% confidenceThe year-over-year improvement in net loss was driven by reduced research and development and general administrative expenses
60% confidenceThe amendment of the VERSATILE-003 trial to include progression-free survival as a primary endpoint potentially reduces trial duration and costs
60% confidence